1228108-64-2Relevant academic research and scientific papers
BI-97C1, an optically pure apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/Leukemia-2 (Bcl-2) family proteins
Wei, Jun,Stebbins, John L.,Kitada, Shinichi,Dash, Rupesh,Placzek, William,Rega, Michele F.,Wu, Bainan,Cellitti, Jason,Zhai, Dayong,Yang, Li,Dahl, Russell,Fisher, Paul B.,Reed, John C.,Pellecchia, Maurizio
, p. 4166 - 4176 (2010)
In our continued attempts to identify novel and effective pan-Bcl-2 antagonists, we have recently reported a series of compound 2 (Apogossypol) derivatives, resulting in the chiral compound 4 (8r). We report here the synthesis and evaluation on its optically pure individual isomers. Compound 11 (BI-97C1), the most potent diastereoisomer of compound 4, inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1, and Bfl-1 with IC 50 values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. The compound also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μM, respectively, and shows little cytotoxicity against bax -/-bak-/- cells. Compound 11 displays in vivo efficacy in transgenic mice models and also demonstrated superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model. Therefore, compound 11 represents a potential drug lead for the development of novel apoptosis-based therapies against cancer.
